Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC

NCT06554613 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

156

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Olanzapine
DRUG: Nivolumab

Sponsor

Second Affiliated Hospital of Nanchang University